IDEXX Laboratories Analyst Ratings
IDEXX Laboratories Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/30/2023 | 18.12% | Stifel | $500 → $460 | Maintains | Hold |
| 09/15/2023 | 28.39% | Stifel | $525 → $500 | Maintains | Hold |
| 08/03/2023 | 54.07% | Morgan Stanley | $590 → $600 | Maintains | Overweight |
| 08/02/2023 | 54.07% | JP Morgan | $550 → $600 | Maintains | Overweight |
| 08/02/2023 | 54.07% | Atlantic Equities | → $600 | Downgrades | Overweight → Neutral |
| 06/07/2023 | 54.07% | Atlantic Equities | → $600 | Reiterates | Overweight → Overweight |
| 05/03/2023 | 54.07% | Atlantic Equities | → $600 | Reiterates | → Overweight |
| 03/23/2023 | 51.51% | Morgan Stanley | $543 → $590 | Maintains | Overweight |
| 02/08/2023 | 51.51% | Barclays | $582 → $590 | Maintains | Overweight |
| 02/07/2023 | 41.23% | JP Morgan | $525 → $550 | Maintains | Overweight |
| 02/07/2023 | 54.07% | Atlantic Equities | $470 → $600 | Maintains | Overweight |
| 01/25/2023 | 36.1% | Goldman Sachs | $465 → $530 | Maintains | Buy |
| 11/15/2022 | 39.44% | Morgan Stanley | $573 → $543 | Maintains | Overweight |
| 11/02/2022 | 20.69% | Atlantic Equities | $490 → $470 | Maintains | Overweight |
| 10/17/2022 | 15.55% | JP Morgan | $525 → $450 | Maintains | Overweight |
| 08/05/2022 | 49.45% | Barclays | $700 → $582 | Maintains | Overweight |
| 08/04/2022 | 47.14% | Morgan Stanley | $603 → $573 | Maintains | Overweight |
| 08/03/2022 | 25.83% | Atlantic Equities | $500 → $490 | Maintains | Overweight |
| 07/26/2022 | 7.85% | Piper Sandler | $440 → $420 | Maintains | Overweight |
| 07/25/2022 | 6.57% | Stifel | $500 → $415 | Downgrades | Buy → Hold |
| 07/21/2022 | 11.7% | Goldman Sachs | $530 → $435 | Upgrades | Neutral → Buy |
| 07/12/2022 | 12.99% | Piper Sandler | → $440 | Initiates Coverage On | → Overweight |
| 06/24/2022 | 28.39% | Stifel | $575 → $500 | Maintains | Buy |
| 05/19/2022 | 36.1% | Goldman Sachs | $615 → $530 | Maintains | Neutral |
| 05/05/2022 | 54.84% | Morgan Stanley | $732 → $603 | Maintains | Overweight |
| 05/05/2022 | 20.69% | B of A Securities | $550 → $470 | Downgrades | Buy → Neutral |
| 02/08/2022 | 66.91% | Atlantic Equities | → $650 | Initiates Coverage On | → Overweight |
| 11/18/2021 | 87.97% | Morgan Stanley | → $732 | Initiates Coverage On | → Overweight |
| 08/13/2021 | 97.73% | Credit Suisse | $735 → $770 | Maintains | Outperform |
| 08/03/2021 | 56.64% | Goldman Sachs | $550 → $610 | Maintains | Neutral |
| 08/02/2021 | 92.59% | Barclays | $616 → $750 | Maintains | Overweight |
| 07/12/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 02/17/2021 | 54.07% | Barclays | → $600 | Initiates Coverage On | → Overweight |
| 01/29/2021 | 46.37% | JP Morgan | → $570 | Initiates Coverage On | → Overweight |
| 08/17/2020 | 8.36% | Credit Suisse | $415 → $422 | Maintains | Outperform |
| 07/30/2020 | -3.7% | Stifel | $280 → $375 | Maintains | Buy |
| 07/20/2020 | 0.15% | B of A Securities | $300 → $390 | Maintains | Buy |
| 05/01/2020 | -28.1% | Stifel | $266 → $280 | Maintains | Buy |
| 09/09/2019 | -28.87% | Goldman Sachs | → $277 | Initiates Coverage On | → Neutral |
| 08/16/2019 | -24.76% | Credit Suisse | $282 → $293 | Maintains | Outperform |
| 07/22/2019 | -24.25% | Stifel | $255 → $295 | Maintains | Buy |
| 05/23/2019 | -29.13% | Guggenheim | → $276 | Initiates Coverage On | → Buy |
| 05/02/2019 | -33.23% | Canaccord Genuity | $255 → $260 | Maintains | Buy |
| 11/05/2018 | -35.8% | Canaccord Genuity | $270 → $250 | Maintains | Buy |
| 11/02/2018 | -39.65% | B of A Securities | $275 → $235 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月30日 | 18.12% | Stifel | $500→$460 | 維護 | 保持 |
| 2023/09/15 | 28.39% | Stifel | $525→$500 | 維護 | 保持 |
| 08/03/2023 | 54.07% | 摩根士丹利 | $590→$600 | 維護 | 超重 |
| 08/02/2023 | 54.07% | 摩根大通 | $550→$600 | 維護 | 超重 |
| 08/02/2023 | 54.07% | 大西洋證券公司 | →$600 | 評級下調 | 超重→中性 |
| 06/07/2023 | 54.07% | 大西洋證券公司 | →$600 | 重申 | 超重→超重 |
| 05/03/2023 | 54.07% | 大西洋證券公司 | →$600 | 重申 | →超重 |
| 03/23/2023 | 51.51% | 摩根士丹利 | $543→$590 | 維護 | 超重 |
| 02/08/2023 | 51.51% | 巴克萊 | $582→$590 | 維護 | 超重 |
| 02/07/2023 | 41.23% | 摩根大通 | $525→$550 | 維護 | 超重 |
| 02/07/2023 | 54.07% | 大西洋證券公司 | $470→$600 | 維護 | 超重 |
| 2023年1月25日 | 36.1% | 高盛 | $465→$530 | 維護 | 買 |
| 2022年11月15日 | 39.44% | 摩根士丹利 | $573→$543 | 維護 | 超重 |
| 11/02/2022 | 20.69% | 大西洋證券公司 | $490→$470 | 維護 | 超重 |
| 10/17/2022 | 15.55% | 摩根大通 | $525→$450 | 維護 | 超重 |
| 08/05/2022 | 49.45% | 巴克萊 | $700→$582 | 維護 | 超重 |
| 08/04/2022 | 47.14% | 摩根士丹利 | $603→$573 | 維護 | 超重 |
| 08/03/2022 | 25.83% | 大西洋證券公司 | $500→$490 | 維護 | 超重 |
| 07/26/2022 | 7.85% | 派珀·桑德勒 | $440→$420 | 維護 | 超重 |
| 07/25/2022 | 6.57% | Stifel | $500→$415 | 評級下調 | 購買→Hold |
| 07/21/2022 | 11.7% | 高盛 | $530→$435 | 升級 | 中性→購買 |
| 07/12/2022 | 12.99% | 派珀·桑德勒 | →$440 | 開始承保 | →超重 |
| 2022/06/24 | 28.39% | Stifel | $575→$500 | 維護 | 買 |
| 2022年05月19日 | 36.1% | 高盛 | $615→$530 | 維護 | 中性 |
| 05/05/2022 | 54.84% | 摩根士丹利 | $732→$603 | 維護 | 超重 |
| 05/05/2022 | 20.69% | B of A證券 | $550→$470 | 評級下調 | 購買→中性 |
| 02/08/2022 | 66.91% | 大西洋證券公司 | →$650 | 開始承保 | →超重 |
| 2021年11月18日 | 87.97% | 摩根士丹利 | →$732 | 開始承保 | →超重 |
| 2021/08/13 | 97.73% | 瑞士信貸 | $735→$770 | 維護 | 跑贏大盤 |
| 08/03/2021 | 56.64% | 高盛 | $550→$610 | 維護 | 中性 |
| 08/02/2021 | 92.59% | 巴克萊 | $616→$750 | 維護 | 超重 |
| 07/12/2021 | - | 古根海姆 | 評級下調 | 購買→中性 | |
| 02/17/2021 | 54.07% | 巴克萊 | →$600 | 開始承保 | →超重 |
| 2021/01/29 | 46.37% | 摩根大通 | →$570 | 開始承保 | →超重 |
| 2020/08/17 | 8.36% | 瑞士信貸 | $415→$422 | 維護 | 跑贏大盤 |
| 07/30/2020 | -3.7% | Stifel | $280→$375 | 維護 | 買 |
| 07/20/2020 | 0.15% | B of A證券 | $300→$390 | 維護 | 買 |
| 05/01/2020 | -28.1% | Stifel | $266→$280 | 維護 | 買 |
| 2019年09月09日 | -28.87% | 高盛 | →$277 | 開始承保 | →中性 |
| 2019年8月16日 | -24.76% | 瑞士信貸 | $282→$293 | 維護 | 跑贏大盤 |
| 2019年07月22日 | -24.25% | Stifel | $255→$295 | 維護 | 買 |
| 2019年05月23日 | -29.13% | 古根海姆 | →$276 | 開始承保 | →購買 |
| 2019年05月02日 | -33.23% | 卡納科特·格納奇 | $255→$260 | 維護 | 買 |
| 2018年11月05日 | -35.8% | 卡納科特·格納奇 | $270→$250 | 維護 | 買 |
| 11/02/2018 | -39.65% | B of A證券 | $275→$235 | 維護 | 買 |
What is the target price for IDEXX Laboratories (IDXX)?
IDEXX實驗室(IDXX)的目標價格是多少？
The latest price target for IDEXX Laboratories (NASDAQ: IDXX) was reported by Stifel on October 30, 2023. The analyst firm set a price target for $460.00 expecting IDXX to rise to within 12 months (a possible 18.12% upside). 14 analyst firms have reported ratings in the last year.
Stifel於2023年10月30日報道了IDEXX實驗室(納斯達克代碼：IDXX)的最新目標價。這家分析公司將目標價定為460.00美元，預計IDXX將在12個月內上漲至18.12%(可能上漲18.12%)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for IDEXX Laboratories (IDXX)?
IDEXX實驗室(IDXX)的最新分析師評級是什麼？
The latest analyst rating for IDEXX Laboratories (NASDAQ: IDXX) was provided by Stifel, and IDEXX Laboratories maintained their hold rating.
IDEXX實驗室(納斯達克代碼：IDXX)的最新分析師評級由Stifel提供，IDEXX實驗室維持持有評級。
When is the next analyst rating going to be posted or updated for IDEXX Laboratories (IDXX)?
IDEXX實驗室(IDXX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on October 30, 2023 so you should expect the next rating to be made available sometime around October 30, 2024.
分析師在進行了廣泛的研究後得出了股票評級，這些研究包括查閱公共財務報表，與IDEXX實驗室的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。IDEXX實驗室的上一次評級是在2023年10月30日提交的，因此您應該預計下一次評級將在2024年10月30日左右的某個時候提供。
Is the Analyst Rating IDEXX Laboratories (IDXX) correct?
分析師評級IDEXX實驗室(IDXX)正確嗎？
While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a maintained with a price target of $500.00 to $460.00. The current price IDEXX Laboratories (IDXX) is trading at is $389.43, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的IDEXX實驗室評級維持不變，目標價在500.00美元至460.00美元之間。IDEXX實驗室目前的交易價格為389.43美元，超出了分析師的預測範圍。